Trial intelligence / Profile preview

Tofacitinib induction in moderate to severe ulcerative colitis (OCTAVE Induction 1)

NCT01465763Phase 3Completed

Sponsor
Pfizer
Start
Apr 2012
Primary completion
May 2015
Modality
Small Molecules
Countries
28
01

Overview

A Phase 3 trial of tofacitinib oral solution in ulcerative colitis (UC), sponsored by Pfizer. Started Apr 2012; status: completed.

02

Drugs

tofacitinib oral solution
03

Conditions

ulcerative colitis (UC)

Beyond the preview

Go deeper on NCT01465763.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01465763.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call